Itriglumide
Product Specifications
UNSPSC Description
Itriglumide (CR 2945) is an anthranilic acid derivative. Itriglumide is a potent and selective CCKB receptor antagonist, with an IC50 of 2.3 nM. Itriglumide antagonizes the response to gastrin in a dose-dependent manner with an IC50 of 5.9 nM. Itriglumide shows antisecretory and antiulcer activity[1].
Target Antigen
Cholecystokinin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein;Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/itriglumide.html
Smiles
O=C(C1=C(C(C)=CC(C)=C1)NC(C[C@@H](C2=CC=CC3=CC=CC=C23)CC(O)=O)=O)N4CCC5(CCCC5)CC4
Molecular Weight
526.67
References & Citations
[1]Makovec F, et al. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist. Eur J Pharmacol. 1999 Mar 12;369(1):81-90.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-106347/Itriglumide-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-106347/
Clinical Information
Phase 2
CAS Number
201605-51-8
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1115974 Inquire
Recombinant Escherichia coli Protein translocase subunit SecA (secA), partial
Ask
View Details 36926141 1x10<sup>6</sup> cells/1.0ml
PLAC8 CRISPR Knock Out 293T Cell Line (Human)
Ask
View Details 